Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL23211912 | 0.93 | OPRD1 (0.54) | OPRD1DPP4DPP7SLC6A2SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL29734556 | 0.87 | OPRD1 (0.52) | OPRD1CACNA1BSMYD3DPP4DPP7 | |
| Trifluoroacetic Acid SCHEMBL30149807 | 0.85 | OPRD1 (0.47) | OPRD1 | |
| SCHEMBL2247018 | 0.85 | OPRD1 (0.57) | OPRD1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL3657538 | 0.83 | OPRD1 (0.56) | OPRD1SLC6A2SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL21381807 | 0.82 | OPRD1 (0.46) | OPRD1DPP4DPP7SLC6A2SLC6A4 | |
| SCHEMBL3660818 | 0.81 | SLC6A2 (0.58) | OPRD1SLC6A2SLC6A4 | |
| Trifluoroacetic Acid SCHEMBL21381685 | 0.79 | OPRD1 (0.44) | OPRD1 | |
| Trifluoroacetic Acid SCHEMBL30567963 | 0.79 | OPRD1 (0.44) | OPRD1 | |
| SCHEMBL21382056 | 0.79 | OPRD1 (0.53) | OPRD1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214578-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200148696-A1 | Urea/Carbamates FAAH MAGL Or Dual FAAH/MAGL Inhibitors And Uses Thereof | NORTHEASTERN UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| US-10570146-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | NORTHEASTERN UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170247387-A1 | UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF | NORTHEASTERN UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| WO-2016014975-A2 | UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF | NORTHEASTERN UNIVERSITY (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214578-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | FAAH, FAAH2, MGLL | OPRD1 850/4885CACNA2D1 3434/4885CACNA1B 1973/4885 |
| US-10570146-B2 | Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof | FAAH, FAAH2, MGLL | OPRD1 364/4885CACNA2D1 4063/4885CACNA1B 2387/4885 |
| US-20170247387-A1 | UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF | FAAH, FAAH2, MGLL | OPRD1 1205/4885CACNA2D1 3795/4885CACNA1B 2192/4885 |
| US-20200148696-A1 | Urea/Carbamates FAAH MAGL Or Dual FAAH/MAGL Inhibitors And Uses Thereof | FAAH, MGLL, FAAH2 | OPRD1 1927/4885CACNA2D1 4593/4885CACNA1B 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.